Mineralys Therapeutics expands board with two new directors

Mineralys Therapeutics, Inc. disclosed in an 8-K filing that on October 16, 2026, the Board of Directors appointed Kristine Peterson and Lonnel Coats to the Board effective as of October 19, 2026, increasing the size of the Board from seven to nine directors.¹

Peterson was appointed as a Class I director, with a term expiring at the Company's 2027 annual meeting of stockholders, and was also appointed to serve as a member of the Audit Committee.¹ Coats was appointed as a Class II director, with a term expiring at the Company's 2028 annual meeting of stockholders, and was also appointed to serve as a member of the Compensation Committee.¹

As compensation, pursuant to the Company's non-employee director compensation program, on October 19, 2026, Peterson and Coats were each granted an option to purchase 16,600 shares of the Company's common stock.¹ The option awards vest in substantially equal monthly installments over a three-year period following October 19, 2026, subject to continued service on the Board.¹ Separately, on October 19, 2026, Peterson and Coats were also each granted a restricted stock unit award covering 12,400 shares of the Company's common stock.¹ The restricted stock unit awards vest in substantially equal annual installments over a three-year period following October 19, 2026, subject to continued service on the Board.¹

The filing states that Peterson and Coats will receive cash compensation for their service on the Board in accordance with the Company's non-employee director compensation program, as such program may be amended from time to time.¹ Both also entered into the Company's standard form of indemnification and advancement agreement, the form of which was filed as Exhibit 10.8 to the Company's Registration Statement on Form S-1 filed with the Securities and Exchange Commission on January 18, 2023.¹

The company noted that there are no arrangements or understandings between either Peterson or Coats and any other person pursuant to which either was selected as a director, and neither is a party to any transaction that would require disclosure under Item 404(a) of Regulation S-K.¹ The Board has determined that each of Peterson and Coats satisfies the applicable independence requirements of The Nasdaq Stock Market LLC.¹